Richard Johnson,MD:Who is Not a Good Candidate for Drugs Like Ozempic? #obesity #weightloss #obesity
Short transcript excerpt of a conversation (Richard Johnson and another speaker) discussing which patients may be poor candidates for GLP-1 agonist drugs. The speaker warns that people with significant gastrointestinal (GI) problems — especially those with gastroparesis, commonly seen in diabetics — may experience exacerbated GI symptoms on GLP-1 agonists, so clinicians should discuss risks case-by-case.
Chapters
More from Dr.
Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health
Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It
Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig
Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet
Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome
Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose
Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance
Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet